- Letter to the Editor Response
- Open Access
Response to Huang et al. “Herpesviridae reactivation for poor outcome in ARDS patients with ECMO: criminal or witness?”
Annals of Intensive Care volume 10, Article number: 8 (2020)
Dear Mr Editor,
Huang et al. recently commented on our publication concerning Herpesviridae reactivation in patients under veno-venous extracorporeal membrane oxygenation (VV ECMO) for severe acute respiratory distress syndrome (ARDS) and raised some important questions. Data available do not allow to conclude once for all, however, we might provide some pieces of answers.
First, the “who?”. In a general population of ARDS patients (without ECMO), Ong et al.  showed that cytomegalovirus (CMV) reactivation among seropositive patients was diagnosed in 27% of patients and 34% among those with concurrent septic shock. In our cohort, CMV reactivation raised 40%, either alone or combined with Herpes Simplex virus (HSV), septic shock being present in nearly all reactivated patients at the time of intensive care unit (ICU) admission. It is not surprising that Herpesviridae reactivation is so common in ARDS patients under ECMO who often combine sepsis and prolonged mechanical ventilation (MV). It would be of high interest to perform a matched controlled study in order to determine if ECMO occurring during ARDS enhances the frequency of Herpesviridae reactivation.
Second, the “how?”. The precise definition of Herpesviridae reactivation or active infection in ICU patients is rather touchy. The positivity of biological samples signs the evidence of viral transition from latency to replication, but end-organ disease symptoms (i.e., pneumonia, hepatitis, colitis, hematological disorders, etc.) can be difficult to identify in such complex patients. One key question would be the comparison of performance diagnosis of blood and airway CMV PCR with antigenemia, which is considered as the reference test in end-organ disease diagnosis. Concerning the timing of HSV and CMV reactivation, Heininger et al. , comparing airway samples, already showed that HSV reactivation occured earlier during MV.
Finally, the “why?”. Several hypotheses have been stated to explain the poor outcomes of patients exhibiting Herpesviridae reactivation during ARDS . Viral pneumonia due to direct lung aggression by HSV or CMV might be the first mechanism. This can be suggested when lung samples are positive but only characteristic histological lesions can affirm such a diagnosis, especially because lung imaging aspects are non-specific. The second mechanism might be an immunopathological effect, in which damage to tissues is caused by the excessive immune response to the virus with prolonged ARDS or evolution towards lung fibrosis. In our cohort, alveolar procollagen III was not different between both groups (24 vs 14% for reactivated and non-reactivated patients), but our study might be underpowered for this comparison and antiviral treatments might have interfered with this result. The third explanation is related to an alteration of patients’ immune defenses, making them more susceptible to fungal and bacterial infections. It would be of high interest to explore immune function in ARDS patients with Herpesviridae reactivation with specific markers such as monocytes HLA-DR expression .
To summarize, despite several decades of research, much remains to be done to lighten the role of Herpesviridae in ARDS patients, and even more in those under ECMO.
Availability of data and materials
acute respiratory distress syndrome
Herpes Simplex Virus
- VV ECMO:
veno-venous extra corporeal membrane oxygenation
Ong DSY, Spitoni C, Klein Klouwenberg PMC, Verduyn Lunel FM, Frencken JF, Schultz MJ, et al. Cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome. Intensive Care Med. 2016;42(3):333–41.
Heininger A, Haeberle H, Fischer I, Beck R, Riessen R, Rohde F, et al. Cytomegalovirus reactivation and associated outcome of critically ill patients with severe sepsis. Crit Care. 2011;15(2):R77.
Papazian L, Hraiech S, Lehingue S, Roch A, Chiche L, Wiramus S, et al. Cytomegalovirus reactivation in ICU patients. Intensive Care Med. 2016;42(1):28–37.
Hegde NR, Tomazin RA, Wisner TW, Dunn C, Boname JM, Lewinsohn DM, et al. Inhibition of HLA-DR assembly, transport, and loading by human cytomegalovirus glycoprotein US3: a novel mechanism for evading major histocompatibility complex class II antigen presentation. J Virol. 2002;76(21):10929–41.
The authors received no funding for this work.
Ethics approval and consent to participate
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Hraiech, S., Papazian, L. Response to Huang et al. “Herpesviridae reactivation for poor outcome in ARDS patients with ECMO: criminal or witness?”. Ann. Intensive Care 10, 8 (2020). https://doi.org/10.1186/s13613-020-0627-3